Introduction
Biomarkers have been extensively investigated as predictors of HIV clinical disease progression (AIDS or death) over the past two decades. This research has been aimed at informing disease pathogenesis among HIVinfected individuals, stratifying patients according to risk of death and serious non-AIDS conditions [e.g., cardiovascular disease (CVD), non-AIDS-defining malignancies, renal disease, and liver disease], and potentially identifying drug targets for future intervention trials.
Biomarker studies are common in many areas of clinical research. In 2001, a National Institutes of Health (NIH) working group developed standard definitions for a biomarker and surrogate outcome. The working group defined a biological marker (biomarker) as 'a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes or pharmacological responses to a therapeutic intervention'. This definition includes measures such as weight and blood pressure, blood tests, measurements based on imaging technology, and genetic variations. The working group defined a surrogate marker as 'a biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiologic, therapeutic, pathophysiological, or other scientific evidence' [1] . A clinical endpoint is a characteristic or variable that reflects how a patient feels, functions, or survives (e.g., death). On the basis of these definitions, surrogate markers can be considered a subset of biomarkers.
The working group classified biomarkers according to the following uses: as a diagnostic tool, as a tool for staging disease, as an indicator of disease prognosis, and for monitoring a response to an intervention. The two biomarkers studied most extensively in HIV research, CD4 þ cell count and HIV RNA level, have been used for all four of the categories mentioned above, but primarily the last three. HIV RNA is considered a surrogate outcome for the clinical endpoint most often used in HIV treatment clinical trials, AIDS-defining conditions or death.
An Institute of Medicine (IOM) Committee adopted these same definitions in their recent report and described the following three steps for evaluating biomarkers: assessment of the analytical performance of the assay; evidence for association between the biomarker and different disease states, including the effects of interventions on both the biomarker and clinical outcomes; and a contextual analysis of the proposed use of the biomarker that includes whether the analytical performance and evidence from the second step provides sufficient support for the proposed use [2 ] .
In this paper, we focus on one aspect of the second step described in the IOM report and review papers investigating the relationship of biomarkers with different disease states among people infected with HIV.
Methods
We searched for studies that related levels of soluble blood biomarkers (i.e., markers that could be measured in plasma or serum) with morbidity and mortality outcomes. We focused on soluble biomarkers because of their ease of collection, storage, and cost. We excluded cellular blood components, including lymphocyte subsets, genetic markers, and diagnostic markers (e.g., serology for hepatitis infection), from our review. We also excluded structural and functional markers that use imaging technologies (e.g., carotid intima-media thickness) and noninvasive measures of endothelial dysfunction. We aimed to identify studies that examined the incremental value (over that of CD4 þ cell count and HIV RNA level) that novel biomarkers had for predicting clinical outcomes. We excluded cross-sectional studies because in these studies a temporal relationship could not be determined. A few studies evaluated markers at multiple time-points (e.g., at baseline and during follow-up). In those cases, we only focused on the baseline measurements.
We searched MEDLINE databases using the following medical subject heading (MeSH) terms: ( A variety of methods were used to study biomarkerclinical outcome associations in the articles and individual patient data were not available for most articles. Thus, our summary, with few exceptions, is largely qualitative and meant to be a potential bibliographic resource for future investigations. Wherever possible, we cite literature from general population cohorts for comparison with the HIV studies we identified. For 25 of 38 studies (66%), the relationship between the biomarker and all-cause mortality was evaluated. For 12 studies (32%), AIDS or the composite outcome AIDS or death was evaluated, two studies examined specific AIDS-defining events, and four studies examined CVD outcomes. All of the studies with a CVD outcome were published in 2008 or later.
Results
Power for detecting associations between biomarkers and clinical outcomes depends on the number of participants who develop the clinical event of interest. Fourteen of the studies had fewer than 50 events (37%), 15 (39%) had more than 50 but fewer than 200 events, and nine (24%) had more than 200 events. Two of the studies with more than 200 events were from the Multicenter AIDS Cohort Study (MACS) and involved follow-up of patients before combination antiretroviral therapy (ART) was available.
Most of the studies used stored samples for the biomarker analyses; however, six of the studies evaluated biomarkers collected as part of routine care (e.g., creatinine and lipids). Eight of the reports utilized a case-control design and most of these were nested within a cohort study or one or more clinical trials. The efficiency of nested case-control studies has been reviewed [50 ] . The other biomarker investigations were cohort studies.
In Table 2 , we categorize the articles listed in Table 1 according to type of biomarker and clinical outcome. Findings are reviewed below. 
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þ cells) as independent predictors of disease progression and mortality. Later studies [54] [55] [56] extended the work on the cellular markers and considered the prognostic importance of cellular markers after adjustment for HIV RNA level and CD4 þ cell count. Recent work on soluble markers that also considered the effects of HIV RNA level and CD4 þ cell count is summarized in this section. In this category of inflammatory and immune activation markers, we include markers that reflect altered expression of cell surface antigens, products of cytokine activity, inflammatory markers, and other soluble markers that may represent immunologic changes. Twenty-four different published reports were identified that related these markers to all-cause mortality, AIDS, the composite outcome of AIDS or death, or CVD.
Associations between b 2 -microglobulin and clinical outcomes have been described in seven reports. In three of the studies [7, 13, 19] , a higher level of b 2 -microglobulin was associated with a significantly increased risk of death. One of these cohorts was described in a second paper that also considered adjustment for CD4 þ CD28 þ cells and the association remained significant with a similar hazard ratio [18] . Three studies [3, 4, 10] found that higher levels were associated with an increased risk of AIDS, but with multivariate adjustment, the association was not significant. One [10] of these latter studies also reported a significant association with mortality that became nonsignificant after adjusting for HIV RNA level, CD4
þ cell count, and other factors.
In all four studies [4,5,17,19] evaluating neopterin, higher levels were associated with an increased risk of clinical outcomes. In one study [19] , the association was not significant. Among the other three studies, one [4] compared the upper tertile versus lower tertile and the relative risk (RR) was 2.9, another [17] compared the upper versus lower quartile and the RR was 2.2, and a third study [5] reported a RR overall 5-6-fold higher for those with neopterin above 20 nmol/l compared with below 12 nmol/l, and 2-3-fold higher for those with neopterin 12-20 versus below 12 nmol/l. The RRs associated with higher neopterin levels in this study [5] were greater among patients with higher CD4 þ cell count and with lower HIV RNA levels.
The HIV-1 antigen, p24, was evaluated in two studies [6, 28] for its effect on progression to AIDS and mortality independent of CD4 þ cell count and HIV RNA level. In both studies, higher levels were associated with an increased risk of progression (RRs were 2.9 for upper versus lower quartile and 1.6 for 10-fold higher levels).
Plasma levels of tumor necrosis factor-alpha (TNFa) were evaluated in five studies [3, 8, 16, 23, 30] . In a study [16] with advanced HIV, higher levels of TNFa were associated with an increased risk of AIDS dementia. No association between TNFa and the development of MAC bacteremia was reported in one small study [8] . TNFa was not related to all-cause mortality [23] and 484 Biomarkers of outcomes of disease, treatment and complications Myeloperoxidase [27] TC, HDL, LDL, triglycerides, total/HDL, total HDL particle, large HDL particle, medium HDL particle, small HDL particle, LDL particle, VLDL particle, HDL size [26, 34, 37] References for the biomarkers in each category are given at the end (see Table 1 for description of study).
AIDS [3, 30] in three other studies, but each study had 50 or fewer events. [30] and TNF-R55 [3] were not associated with progression to AIDS. One study [4] found that higher levels of TNF-R75 were associated with AIDS and one study [3] did not. Likewise, results for TNF-RII were inconsistent. One study [5] found an association with AIDS, whereas two [8,36] did not. One study [36] reported a significant association between higher levels of TNF-RI and AIDS or death (hazard ratio ¼ 3 for a 615 pg/ml higher level).
Several of the inflammatory markers studied in HIV cohorts have also been studied in general population cohorts. Two frequently studied markers were C-reactive protein (CRP) and interleukin (IL)-6. The relationship of CRP with all-cause mortality was evaluated in the Women's Interagency HIV Study (WIHS), a study of pregnant women in Tanzania, the Strategies for Management of Anti-Retroviral Therapy (SMART) study, and the Fat Redistribution and Metabolic Change in HIV Infection (FRAM) study [12,25,29 ,39] . In all four studies, CRP was significantly related to all-cause mortality after adjustment for HIV RNA, CD4
þ cell count, and other factors. RR/odds ratio (OR) estimates for the upper versus lowest quartile of CRP ranged from 1.7 in the Tanzanian study to 4.5 in WIHS. SMART was intermediate (RR ¼ 3.1). In FRAM, the adjusted OR estimates for the upper versus lowest quartile of CRP was 3.7.
In the Tanzanian study and in SMART, the association of CRP with AIDS was also evaluated. Significant associations were found in both studies [25, 33] with RRs for the upper versus lowest quartile of CRP of 1.9 and 3.5. A report from the MACS preceded these studies and also found a significant association between CRP and AIDS. For those in the upper quartile of CRP (>2.3 mg/l) versus those 1.2 mg/l or less (lower 54% of the distribution), the RR was 2.0 [22] . In the Tanzanian study, a significant association between CRP and the composite outcome of AIDS or all-cause mortality was also reported with a RR (upper versus lowest quartile) equal to 2.2.
An overview of the association between CRP and allcause mortality and between CRP and CVD outcomes in the general population has recently been published [57] . The authors concluded that associations of CRP with vascular and nonvascular mortality were similar. Graded relationships with CRP were evident for both outcomes.
Like CRP, IL-6 has been studied with different clinical outcomes. In SMART, the association between IL-6 and all-cause mortality was much greater than for CRP. The RR (upper versus lowest quartile) of IL-6 was 12.4 [29 ] . Three studies reported significant associations between IL-6 and AIDS [33] or between IL-6 and AIDS or death [17, 36] . These associations, though significant, were not as strong as the association between IL-6 and all-cause mortality found in SMART but are similar to the association between CRP and AIDS. In one small study [8] of disseminated MAC, there was no difference in IL-6 found among patients who developed MAC bacteremia and those who did not.
IL-6 has been shown to be related to both CVD and allcause mortality in the general population [58] [59] [60] . For a number of years, it has been recognized that IL-6 levels are elevated with HIV infection [61] . Recently, the magnitude of this elevation for both IL-6 and CRP has been quantified among HIV-infected patients on combination ART and with suppressed HIV RNA levels [62 ] .
In SMART, amyloid A and amyloid P, two other markers that have been evaluated in general population cohorts [63, 64] were studied in relation to all-cause mortality and AIDS. Higher levels of amyloid A and lower levels of amyloid P were seen for both outcomes, but the associations were not graded [29 ,33] . To date, these markers have not been studied in other HIV cohorts.
Four studies [7, 18, 19, 24] evaluated soluble urokinasetype plasminogen activator receptor (suPAR) as a predictor of clinical outcomes. After adjusting for CD4 þ cell count and HIV RNA level, higher levels of suPAR were associated with all-cause mortality in three [7, 18, 24 ] of these reports. Two studies considered the increased risk associated with a 1 ng/ml increase in suPAR and hazard ratios were 1.6 [7] and 2.5 [18] . A third study [24] considered the risk associated with a 1 log increase in suPAR and the hazard ratio was 10.0.
Associations with IL-2 receptor (IL-2R) were reported in two studies. One study found IL-2R to be associated with progression to AIDS [5] and the other [14] found an association with all-cause mortality.
A number of other markers related to immune activation have been evaluated in single studies. Immunoglobulin A was associated with AIDS and all-cause mortality in univariate analyses; however, the associations were not significant after multivariate adjustment [10] . Another study evaluated TNF-beta (TNFb) and APO-1/Fas levels and found that patients who progressed to AIDS had higher TNFb levels and lower APO-1/Fas levels compared with those who did not [3] . A small study [8] of disseminated MAC, evaluated transforming growth factor-beta (TGF-b) and IL-10, and differences between those who developed MAC and those who did not were not significant. A study [14] including patients with advanced HIV who were initiating ART evaluated Eselectin and soluble intercellular adhesion molecule-1 (ICAM-1) (IL-2R was also evaluated -see above). Higher levels of ICAM-1 were associated with mortality in univariate but not in multivariate analyses. In a study [30] that examined glutathione tripeptide (GSH) and GSH peroxidases, these markers were not associated with progression to AIDS. Finally, in a study [36] that also evaluated other markers, soluble CD27 and CD40L were evaluated. Higher levels of both CD27 and CD40L were associated with an increased risk of AIDS or death. The association was significant for CD40L, but not CD27, after adjustment.
Only one published study investigating an inflammatory marker and CVD was found. This case-control study [27] investigated myeloperoxidase and found no association with CVD. Levels were actually lower in CVD patients (292 pmol/l) than matched controls (320 pmol/l).
Hemostatic markers
In SMART, D-dimer and prothrombin fragment 1þ2 were studied in relation to both all-cause mortality and AIDS [29 ,33] . The association of D-dimer with allcause mortality was striking (RR for fourth versus first quartile ¼ 41, P < 0.0001), but was not significantly associated with AIDS [33] . Like IL-6 and CRP, D-dimer levels were elevated even among participants with suppressed HIV RNA level [62 ] .
Recent abstracts [42, 46, 48] have confirmed the association of D-dimer with mortality that was found in SMART. D-dimer has also been related to all-cause mortality and CVD in the general population [65, 66] , but the strength of the association was not as strong as seen in studies of HIV participants.
In FRAM [39] , fibrinogen was evaluated. Higher fibrinogen levels were associated with an increased risk of death (OR for upper versus lowest tertile ¼ 2.6). Fibrinogen is associated with vascular and nonvascular mortality in the general population [67] .
Lipid markers
Four studies reported associations between lipids/lipoproteins and clinical outcomes. Three of the four studies reported associations with CVD outcomes. In the single study that reported associations with all-cause mortality, the associations with non-high-density lipoprotein (HDL)-cholesterol and HDL-cholesterol were weak (P ¼ 0.05 and 0.06, respectively) after adjustment for CD4 þ cell count, HIV RNA level, and CVD risk factors. Higher levels of both lipid fractions were associated with lower mortality [37] .
The largest study to examine the association between lipids and CVD is the Data collection on Adverse events of anti-HIV Drugs (D:A:D) study [38] . In DAD, total cholesterol (TC) and HDL-cholesterol were significantly associated (positive association for TC and inverse for HDL) with an increased risk of CVD, coronary heart disease, and myocardial infarction (MI). A recent abstract [49] from the DAD study reported that triglycerides were associated with MI independent of both TC and HDLcholesterol.
Two reports from SMART have been published. In the first report, associations between usual lipid values with CVD were reported. In the continuous ART group, TC and the TC/HDL-cholesterol ratio were significantly associated with CVD [26] . The second report examined lipoprotein particle concentrations by nuclear magnetic resonance. Total, large, and small HDL particle concentrations were significantly inversely associated with CVD, but very-low-density lipoprotein and low-density lipoprotein (LDL) particle concentrations were not [34] . The findings on usual lipids are in general agreement with a large body of evidence and an overview of studies carried out in the general population [68] . SMART is the only study that has evaluated the relationship of lipid particle concentrations and CVD in HIV-infected persons. The absence of an association of LDL particle concentrations with CVD in SMART, particularly small LDL particles, is in contrast to some studies in the general population [69, 70] .
Other markers
The two most frequent markers studied in this category were albumin and creatinine and/or estimated glomerular filtration rate (eGFR). Biomarkers related to iron status were examined in two reports and the other markers were examined in single studies.
Associations between albumin levels and clinical outcomes were evaluated in four studies [10, 15, 20, 21] . In each of these reports, reduced levels of albumin were associated with an increased risk of all-cause mortality. Two [10, 21] of these studies also reported the relationship between lower albumin levels and progression to AIDS. In the general population, lower albumin levels are associated with an increased risk of heart disease and allcause mortality [71] .
Four studies [9, 11, 35, 40] evaluated creatinine or eGFR. One [9] reported an increased risk of death associated with lower creatinine level (<80 mmol/l for men and <70 mmol/l for women). The other three studies found an increased risk of all-cause mortality with higher levels of creatinine (1.4 versus <1.4 mg/dl) [11] and lower levels eGFR (<30 versus 30 ml/min/1.73 m 2 or <60 versus 60 ml/min/ 1.73 m population cohorts found that risk of death for eGFRs below 75 ml/min per 1.73 m 2 increased in a graded fashion.
Two studies [31, 32] evaluated the relationship between ferritin and all-cause mortality. In both of these reports, higher levels of ferritin were associated with an increased risk of death. One [32] of these studies also examined the iron status biomarkers transferrin receptor (TfR), transferrin, transferrin index, the TfR/ferritin ratio (TfR:F), and iron. After adjustment for CD4 þ cell count, HIV RNA level and other factors, lower levels of transferrin and TfR:F, and higher levels of transferrin index were also associated with an increased risk of death.
A number of other markers were examined in individual studies. One study [10] evaluated aspartate transaminase (AST), bilirubin, and g-glutamyl transpeptidase (GGT). These three markers were not associated with progression to AIDS or to all-cause mortality. GGT was univariately, but not multivariately, associated with AIDS and death. There was also a univariate association between AST and all-cause mortality, but this relationship did not remain significant after adjustment. One study [35] reported an increased risk of death with higher fibrosis index (FIB) 4 levels.
Discussion
We identified 38 papers on the relationship of biomarkers with clinical outcomes. Most studies used stored specimens to measure biomarkers and for one-half of the studies, patients were enrolled in 1998 or before. The former statistic illustrates the potential importance of specimen repositories; the latter statistic and the small number of reports overall likely reflect the fact that as potent ART became available, large cohorts with long follow-up are needed to accrue cases for biomarker studies as the risk of clinical events is low. The small number of studies investigating biomarkers with non-AIDS conditions (four with CVD outcomes) may reflect both the low risk of these outcomes and the fact that serious non-AIDS conditions have not been recognized as major causes of morbidity and mortality due possibly to both HIV infection and to complications of combination ART until the last few years. Many of the biomarkers have only been evaluated in one study, and many studies were small. Fourteen studies had 50 or fewer events.
The determinants of biomarker levels may differ for HIV-infected and noninfected participants. Thus, replication of studies in HIV cohorts may be important even when there is a substantial literature for the biomarker based on general population cohorts. A recent review [73] discusses this for CVD outcomes. The data reviewed herein support this. Elevated D-dimer levels appear to be associated with a greater risk of death among HIV participants than in general population cohorts. And, on the contrary, LDL-cholesterol, particularly small LDL particle concentrations do not appear to be as strongly related to CVD outcomes among HIV participants as they are in the general population.
Large studies with long follow-up, carefully documented clinical events, and specimen repositories are needed to advance research on HIV biomarkers. Cohort studies and clinical trials are ideal for nesting case-control studies once a large number of clinical events have occurred [50 ] . The use of such studies enables good documentation of the target population from which both the cases and controls were chosen. With the clinical data and stored specimens for biomarker measurements, it should be possible to efficiently study novel biomarkers that may lead to improved systems for risk-stratifying patients for AIDS and serious non-AIDS diseases. In HIV, this has already been done with HIV RNA and CD4 þ cell count [74] and to some extent with other readily available laboratory tests [35] . Such risk stratification could be important for targeting treatments including the initiation of ART. Substantial biomarker research is ongoing in several other fields [75] [76] [77] , and given the recent interest in risk of serious non-AIDS events [78] , HIV research appears to be poised for an increase in such research. Thus, we would expect to see an increasing number of reports in the future concerning novel biomarkers to classify patients according to risk of specific non-AIDS conditions.
As noted in the IOM report, the evaluation of biomarkers requires multiple steps and several studies [2 ] . This review was aimed at identifying studies that examined associations between biomarkers and clinical outcomes. An important step, which we did not address, is the analytical performance of the different assays. Also critical to the evaluation of biomarkers and ultimately impacting morbidity and mortality, we did not review studies on interventions aimed at modifying biomarkers that are associated with increased risk of disease.
Multiple clinical trials will be needed that include both biomarker measurements and clinical outcomes to ensure that a biomarker can be safely used as a substitute for a clinical outcome in predicting the effect of an intervention. As noted in a classic paper [79] on surrogate markers -'a correlate does not a surrogate make'. Experience with research aimed at establishing HIV RNA level and CD4
þ cell count as surrogate markers for progression of AIDS illustrates that point. These two biomarkers have been studied extensively for predicting AIDS events and mortality, for staging disease and as outcomes in clinical trials. The MACS established that single measurements of HIV RNA and CD4 þ cell count were important determinants of AIDS or death [80 ] . Even though both HIV RNA level and CD4 þ cell count are strongly related to risk of AIDS and all-cause mortality, and ART significantly impacts these markers, it took some time for HIV RNA to be accepted as a surrogate marker for clinical disease progression. A key step in the evaluation of surrogacy for HIV RNA level and CD4 þ cell count was a meta-analysis of industry and governmentfunded clinical trials that involved over 13 000 patients with HIV RNA and CD4 þ measurements and clinical outcome assessments [81 ] .
Conclusion
In summary, initial research on biomarkers for predicting HIV progression focused on virologic and immunologic markers. Once HIV RNA levels and CD4 þ cell count became widely used, HIV biomarker research slowed. There now seems to be resurgence. Our review only considered soluble blood markers. Future research will likely also include functional markers, genetic biomarkers, and a full array of technologies now available in 'omics' toolboxes. Although we can build on research findings in general population cohorts, it will be important to study biomarkers in HIV-infected cohorts and clinical trials. Future growth of this field of research will require large studies with carefully collected clinical data and specimen repositories.
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